Inhibition TGF-β pathway to prevent cardiac fibrosis of SHSST cyclodextrin complex on cirrhotic-cardiomyopathy rat hearts

Wei-Wen Kuo¹, Dennis Jine-Yuan Hsieh², Cheng-Hsun Yang³, Yuhsin Tsai³, Wei-Jen Ting⁴, and Chih-Yang Huang^{2,3,5,*}

 ¹Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
²School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
³School of Chinese Medicine, China Medical University
⁴Graduate Institute of Basic Medical Science, China Medical University, Taiwan
⁵Department of Health and Nutrition Biotechnology, Asia University, Taiwan

Abstract

Patients with liver cirrhosis also have subtle abnormalities of cardiac structure or function, and this cardiac dysfunction happens commonly in 56% of waiting orthotopic liver transplantation (OLT) patients and was defined as cirrhotic cardiomyopathy (CCM). Up to now, there is no standard treatment because CCM does not have a solidly established diagnosis and is based on high clinical suspicion. Particularly, the liver function is very limited of CCM patients to suffer more drugs treatments. Here, we use silymarin (100mg/kg/day), baicalein (30mg/kg/day), San Huang Shel Shin Tang (SHSST, 30mg/kg/day) and β-cyclodextrin modified SHSST (SHSSTc, 30mg/kg/day and 300mg/kg/day) treatments for CCl₄-induced CCM rat model. As the results shown that silymarin, baicalein and SHSST treatments can only slightly reduced the collagen acumination in CCM rat hearts. But SHSSTc treatment protect the heart in CCM and inhibited collagen acumination significantly and also inhibited the fibrosis regulate transforming growth factor (TGF- β) pathway expressions. SHSSTc treatments further reduced the heart weight and the ratio between left vestibular weight (LVW) and tibia length (TL). These experimental evidences shown the water solubility improved β-cyclodextrin modified Chinese herbal medicine formula (SHSSTc) can provide an excellence heart protection effect through TGF- β pathway inhibition.

Keywords: TGF-β pathway, cardiac fibrosis, San Huang Shel Shin Tang; cirrhotic cardiomyopathy